PURPOSE: To study the efficacy and tolerance of certolizumab pegol (CZP) in active uveitis. METHODS: Retrospective case series at 4 referral centers. Patients treated with CZP for active uveitis during at least 6 months were eligible. Inflammation by SUN scores, visual acuity (VA) (logMAR), and central macular thickness (CMT) were compared from baseline until final follow-up. Quiescence was defined as 0+ to 0.5+ in anterior chamber and vitreous haze scores and no CMT increase. RESULTS: Four males and 3 females (14 eyes) were included, mean age 42.4 ± 8.8 years. All were long-lasting chronic-relapsing uveitis with prior failure to other anti-TNF-α. After a mean follow-up of 10.4 ± 4.8 months, 5/7 patients (71.4%) achieved quiescence with CZP. VA improved significantly from +0.52 ± 0.68 to +0.45 ± 0.68 (p = 0.032) at 1 month and to +0.44 ± 0.64 (p = 0.035) at 6 months. No adverse events were found. CONCLUSION: CZP can be an effective alternative in refractory uveitis.
PURPOSE: To study the efficacy and tolerance of certolizumab pegol (CZP) in active uveitis. METHODS: Retrospective case series at 4 referral centers. Patients treated with CZP for active uveitis during at least 6 months were eligible. Inflammation by SUN scores, visual acuity (VA) (logMAR), and central macular thickness (CMT) were compared from baseline until final follow-up. Quiescence was defined as 0+ to 0.5+ in anterior chamber and vitreous haze scores and no CMT increase. RESULTS: Four males and 3 females (14 eyes) were included, mean age 42.4 ± 8.8 years. All were long-lasting chronic-relapsing uveitis with prior failure to other anti-TNF-α. After a mean follow-up of 10.4 ± 4.8 months, 5/7 patients (71.4%) achieved quiescence with CZP. VA improved significantly from +0.52 ± 0.68 to +0.45 ± 0.68 (p = 0.032) at 1 month and to +0.44 ± 0.64 (p = 0.035) at 6 months. No adverse events were found. CONCLUSION:CZP can be an effective alternative in refractory uveitis.
Authors: Thomas Greuter; Florian Rieder; Torsten Kucharzik; Laurent Peyrin-Biroulet; Alain M Schoepfer; David T Rubin; Stephan R Vavricka Journal: Gut Date: 2020-08-26 Impact factor: 31.793
Authors: M Rudwaleit; J T Rosenbaum; R Landewé; H Marzo-Ortega; J Sieper; D van der Heijde; O Davies; H Bartz; B Hoepken; T Nurminen; A Deodhar Journal: Arthritis Care Res (Hoboken) Date: 2016-06 Impact factor: 4.794
Authors: Obinna C Ubah; John Steven; Marina Kovaleva; Laura Ferguson; Charlotte Barelle; Andrew J R Porter; Caroline J Barelle Journal: Front Immunol Date: 2017-12-22 Impact factor: 7.561